A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Name: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Published: 2023
License: Public Domain

Lei Zheng · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

antibody immunotherapy pancreatic-cancer

pancreatic cancer, adenocarcinoma, resectable pancreas cancer, tislelizumab, anti-pd-1, pd-l1, antibody, sx-682, cxcr1/2 (chemokine receptor), cxcr1/2 inhibitor, small molecule, immunotherapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 881553
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.